Neoadjuvant chemotherapy for intrahepatic, perihilar, and distal cholangiocarcinoma: a national population-based comparative cohort study.
Abstract
There were 9411 patients undergoing surgery for iCCA (n = 3772, 39.5%), hCCA (n = 1879, 20%), and dCCA (n = 3760, 40%). Of these, 10.6% (n = 399), 6.5% (n = 123), and 7.2% (n = 271) with iCCA, hCCA, and dCCA received NAC, respectively. On adjusted analyses, patients receiving NAC followed by surgery had significantly improved OS, compared to SA for iCCA (HR 0.75, CI95% 0.64-0.88, p < 0.001), hCCA (HR 0.72, CI95% 0.54-0.97, p = 0.033), and for dCCA (HR 0.65, CI95% 0.53-0.78, p < 0.001). However, sensitivity analyses demonstrated no differences in OS between NACs, followed by surgery or AC after surgery in iCCA (HR 1.19, CI95% 0.99-1.45, p = 0.068), hCCA (HR 0.83 CI95% 0.59-1.19, p = 0.311), and dCCA (HR 1.13 CI95% 0.91-1.41, p = 0.264).
Citations
Altmetric:
Date
2023-02-07
Type
Article
Subject
Surgery, Oncology. Pathology.
Citation
Parente A, Kamarajah SK, Baia M, Tirotta F, Manzia TM, Hilal MA, Pawlik TM, White SA, Dahdaleh FS. Neoadjuvant Chemotherapy for Intrahepatic, Perihilar, and Distal Cholangiocarcinoma: a National Population-Based Comparative Cohort Study. J Gastrointest Surg. 2023 Apr;27(4):741-749. doi: 10.1007/s11605-023-05606-y. Epub 2023 Feb 7.
Journal / Source Title
Journal of Gastrointestinal Surgery
DOI
10.1007/s11605-023-05606-y
PMID
36749556
Publisher
Elsevier
Publisher’s URL
https://link.springer.com/journal/11605